Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
87
0
2

Year Published

2020
2020
2022
2022

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 108 publications
(92 citation statements)
references
References 26 publications
3
87
0
2
Order By: Relevance
“…Based on these results, two phase III studies were undertaken. First, the SANET-ep study (NCT02588170) included 198 patients with extra-pancreatic NETs that were randomized 2:1 to receive surufatinib 300 mg daily (n = 129) or placebo (n = 69) [91]. The most common primary tumor site was the rectum (27% of patients), followed by the lung, thymus, stomach and small bowel (8%).…”
Section: Surufatinibmentioning
confidence: 99%
“…Based on these results, two phase III studies were undertaken. First, the SANET-ep study (NCT02588170) included 198 patients with extra-pancreatic NETs that were randomized 2:1 to receive surufatinib 300 mg daily (n = 129) or placebo (n = 69) [91]. The most common primary tumor site was the rectum (27% of patients), followed by the lung, thymus, stomach and small bowel (8%).…”
Section: Surufatinibmentioning
confidence: 99%
“…The EVINEC phase II trial has evaluated the safety and tolerability of everolimus as second-line treatment in NEC and NET G-3, but results are not yet available (NTC02113800). Recently, surufatinib, a novel multi-target inhibitor, has shown positive effects in progression-free survival (PFS) for extra-pancreatic NET of low and intermediate grades vs. placebo, with no data in NET G-3 [ 96 ]. Overall, results with everolimus and sunitinib in NET G-3 need confirmation in larger populations and cannot currently be proposed as first-line treatment.…”
Section: Treatmentmentioning
confidence: 99%
“…Two randomized phase III placebo controlled trials evaluated safety and efficacy of surufatinib in patients with well differentiated NENs of extra-pancreatic (SANET-ep) and pancreatic (SANET-p) origin ( 70 , 71 ).…”
Section: Fgfrs As Therapeutic Target In Nensmentioning
confidence: 99%
“…In SANET-ep study ( 70 ) 198 patients were randomly assigned to surufatinib 300 mg/day (n=129) or placebo (n=69). Median progression-free survival (PFS) was 9.2 months in the surufatinib group versus 3.8 months in the placebo group.…”
Section: Fgfrs As Therapeutic Target In Nensmentioning
confidence: 99%